Added to YB: 2026-05-20
Pitch date: 2026-05-15
GSK [neutral]
GSK plc
+2.51%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 74.4B
Pitch Price
GBP 18.55
Price Target
N/A
Dividend
3.87%
EV/EBITDA
7.70
P/E
13.12
EV/Sales
2.73
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 15/5/2026 - GSK – Pipeline progress
GSK (update): Partnered w/ China's SBP to accelerate bepirovirsen launch for chronic hep B (75M patients in China). Priority Review in China (Apr), US & Japan. Trading 9.7x 2027 EPS, 4.0% yield—cheapest large cap pharma. Significant market opportunity if approved.
Read full article (1 min)